Eli Lilly just gave investors several reasons to cheer.
"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...
Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...
Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
8d
Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...
Dow, S&P 500, and Nasdaq futures are dropping in premarket trading Friday ahead of the PCE inflation report and as a federal government shutdown looms.
The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback